IP Library Granted Patent US 12,735,443
Granted Patent B2
US 12,735,443 · App. 17/612,511 · Granted Sep 15, 2026

Purification of oligosaccharides from a fermentation broth by using filtration

Inventors: Stefan Jennewein (Bad Honnef, DE); Jan Henrik Krahn (Sankt Augustin, DE); Markus Helfrich (Bad Hoenningen, DE)
Assignee: Chr. Hansen A/S
C07H1/06A23L33/40B01D61/025B01D61/026B01D61/027B01D61/145B01D61/146B01D61/147B01D61/422B01D61/58B01D69/02C08B37/0003A23V2002/00B01D2311/04B01D2311/06B01D2311/2626B01D2311/2676B01D2315/16B01D2325/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,735,443
App. No.
17/612,511
Granted
Sep 15, 2026
Kind
B2
Abstract

Disclosed is method for the purification of an oligosaccharide of interest from a fermentation broth, the method comprises providing a cell-free fermentation broth to a first filtration step using a nanofiltration membrane, thereby providing a filtrate which contains the oligosaccharide of interest; subjecting the filtrate to a second filtration step using a nanofiltration membrane, thereby providing a retentate which contains the oligosaccharide of interest; and removing salts from the retentate thereby providing a purified preparation of the oligosaccharide of interest.

Claims (38)

1 . A method for purification of an oligosaccharide of interest from a fermentation broth, wherein the method comprises:

(i) providing a fermentation broth which comprises the oligosaccharide of interest, biomass, microbial cells and carbohydrates other than the oligosaccharide of interest;

(ii) removing the microbial cells from the fermentation broth, thereby providing a process stream;

(iii) subjecting the process stream to a first filtration using a nanofiltration membrane, thereby providing a filtrate which contains the oligosaccharide of interest, wherein the nanofiltration membrane used in the first filtration has a molecular weight cut-off of between about 700 Dalton and about 3,000 Dalton;

(iv) subjecting the filtrate to a second filtration using a nanofiltration membrane, thereby providing a retentate which contains the oligosaccharide of interest, wherein the nanofiltration membrane used in the second filtration has a molecular weight cut-off between 100 Dalton and 1,000 Dalton; and

(v) removing one or more salts from the process stream using electrodialysis thereby providing a purified preparation of the oligosaccharide of interest

wherein the method does not comprise an ion exchange step.

2 . The method according to claim 1 , wherein the microbial cells are removed from the fermentation broth by subjecting the fermentation broth to at least one centrifugation and/or to at least one filtration.

3 . The method according to claim 2 , wherein the at least one filtration is a microfiltration.

4 . The method according to claim 3 , wherein the process stream is subjected to at least one ultrafiltration, using a membrane having a molecular weight cut-off of about 50 kDa.

5 . The method according to claim 1 , wherein the nanofiltration membrane used in the first filtration has a molecular weight cut-off of about 1,000 and about 2,000 Dalton.

6 . The method according to claim 1 , wherein the nanofiltration membrane used in the second filtration has a molecular weight cut-off of about 150 Dalton and about 500 Dalton.

7 . The method according to claim 1 , wherein the oligosaccharide of interest is a HMO selected from the group consisting of 2′-fucosyllactose, 3-fucosyllactose, 2′, 3-difucosyllactose, lacto-N-triose II, lacto-N-tetraose, lacto-N-neotetraose, lacto-N-fucopentaose I, lacto-N-neofucopentaose, lacto-N-fucopentaose II, lacto-N-fucopentaose III, lacto-N-fucopentaose V, lacto-N-neofucopentaose V, lacto-N-difucohexaose I, lacto-N-difucohexaose II, 6′-galactosyllactose, 3′-galactosyllactose, lacto-N-hexaose and lacto-N-neohexaose 3′-sialyllactose, 6′-sialyllactose, sialyllacto-N-tetraose a, sialyllacto-N-tetraose b, sialyllacto-N-tetraose c, 3-fucosyl-sialyllactose, disialyl-lacto-N-tetraose and fucosyl-LST b, or any other HMO as listed in Table 1.

8 . The method according to claim 1 , wherein the process stream is subjected to the second filtration such that

i) the amount of salt in the retentate is <10%-wt., and/or

ii) the conductivity is between 0.5 and 10.0 mS/cm 2 .

9 . The method according to claim 1 , wherein the process stream is subjected to a concentration.

10 . The method according to claim 9 , wherein the concentration is performed

by nanofiltration at a temperature of <80° C.; and/or

by reverse osmosis at a temperature of 20° C. to 50° C.; and/or

at a pressure between >5 bar and <50 bar.

11 . The method according to claim 1 , wherein the process stream is subjected to a concentration such that the concentration of the oligosaccharide of interest is ≥100 g/L.

12 . The method according to claim 1 , wherein the process stream is subjected to removal of one or more colorants.

13 . The method according to claim 12 , wherein the removing of colorants is performed

i) before or after diafiltration;

ii) before or after concentrating the process stream; and/or

iii) before or after electrodialysis.

14 . The method according to claim 1 , wherein the electrodialysis is an electrodialysis under neutral conditions or an electrodialysis under acidic conditions.

15 . The method according to claim 1 , wherein the process stream after removal of one or more salts contained therein

i) comprises an amount of salt that is <1%-wt.; and/or

ii) has a conductivity of between 0.05 and 1.0 mS/cm 2 .

16 . The method according to claim 1 , wherein the process stream is spray-dried, preferably optionally spray dried

i) at an inlet temperature in the range of 110-150° C. and an outlet temperature in the range of 60-80° C.; and/or

ii) at a concentration of the oligosaccharide of interest in the process stream of 5-60%-wt.

17 . The method according to claim 1 , wherein the purity of the oligosaccharide of interest in the purified preparation is ≥80%-wt., with respect to dry matter of the purified preparation.

18 . The method according to claim 3 , wherein the microfiltration comprises using a membrane which has a molecular weight cut-off of about 500 kDa.

19 . The method according to claim 3 , wherein the microfiltration comprises using a membrane which has a molecular weight cut-off of about 150 kDa.

20 . The method according to claim 3 , wherein the process stream is subjected to at least one ultrafiltration, using a membrane having a molecular weight cut-off of about 30 kDa.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2026
From: JENNEWEIN, STEFAN; KRAHN, JAN HENRIK; HELFRICH, MARCUS
To: CHR. HANSEN A/S
Reel/Frame 074895/0256 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2025
From: CHR. HANSEN HMO GMBH
To: CHR. HANSEN A/S
Reel/Frame 070396/0299 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 6, 2023
From: JENNEWEIN, STEFAN; KRAHN, JAN HENRIK; HELFRICH, MARCUS
To: CHR HANSEN HMO GMBH
Reel/Frame 065785/0404 →
Priority Claims (1)
EP 19175716 · May 21, 2019 · regional
Continuity (1)
Related Publication 20220251130A1 · Aug 11, 2022
References Cited (49)
US 5057326A · Sampson · 1991 [cited by applicant]
US 7521212B1 · Samain et al. · 2009 [cited by applicant]
US 10377787B2 · Jennewein · 2019 [cited by examiner]
US 10435427B2 · Jennewein et al. · 2019 [cited by applicant]
US 10882880B2 · Jennewein · 2021 [cited by examiner]
US 11168105B2 · Jennewein · 2021 [cited by examiner]
US 11597740B2 · Jennewein · 2023 [cited by examiner]
US 11834691B2 · Jennewein · 2023 [cited by examiner]
US 11912735B2 · Jennewein · 2024 [cited by examiner]
US 20040167220A1 · Horst et al. · 2004 [cited by applicant]
US 20070002073A1 · Baik et al. · 2007 [cited by applicant]
US 20070020736A1 · Samain · 2007 [cited by applicant]
US 20160237104A1 · Jennewein et al. · 2016 [cited by applicant]
US 20200231618A1 · Jennewein · 2020 [cited by applicant]
US 20200308211A1 · Jennewein et al. · 2020 [cited by applicant]
US 20210061836A1 · Jennewein · 2021 [cited by applicant]
KR 20160132009A · 2016 [cited by applicant]
WO 2009135252A1 · 2009 [cited by applicant]
WO 2010106320A2 · 2010 [cited by applicant]
WO 2010115935A1 · 2010 [cited by applicant]
WO 2015049331A1 · 2015 [cited by applicant]
WO WO2015106943A1 · 2015 [cited by examiner]
WO 2016095924A1 · 2016 [cited by applicant]
WO 2017182965A1 · 2017 [cited by applicant]
WO 2018020473A1 · 2018 [cited by applicant]
WO 2019043029A1 · 2019 [cited by applicant]
WO 2019215073A1 · 2019 [cited by applicant]
Geisser et al, Journal of Chromatography A, 2005, 1092, 17-23. [cited by examiner]
Stefan Weichert, et al., “Structural basis for norovirus inhibition by human milk oligosaccharides,.” Journal of Virology, (2016), vol. 90, No. 9: 4843-4848. [cited by applicant]
L. Bode, “Human milk oligosaccharides: Every baby needs a sugar mama,” Glycobiology, (2012), vol. 22, No. 9 :1147-1162. [cited by applicant]
L. Bode and E. Jantscher-Krenn, “Structure-Function Relationships of Human Milk Oligosaccharides,” Advances in Nutrition, (2012), vol. 3, No. 3: 383S-391S. [cited by applicant]
Florian Baumgartner, et al., “Construction of [cited by applicant]
Bernard Priem, et al., “A new fermentation process allows large-scale production of human milk oligosaccharides by metabolically engineered bacteria,” Glycobiology, (2002), vol. 12, No. 4 : 235-240. [cited by applicant]
Stefan Weichert, et al., “Bioengineered 2′-fucosyllactose and 3-fucosyllactose inhibit the adhesion of Pseudomonas aeruginosa and enteric pathogens to human intestinal and respiratory cell lines,” Nutrition research, (2… [cited by applicant]
Trisha Gura, “Nature's first functional food,” Science, (2014), vol. 345, No. 6198: 747-749. [cited by applicant]
Ardythe L. Morrow, et al., “Human milk oligosaccharides are associated with protection against diarrhea in breast-fed infants,” The Journal of Pediatrics, (2004), vol. 145, No. 3: 297-303. [cited by applicant]
International Search Report for Application No. PCT/EP2020/061888 mailed Aug. 5, 2020. [cited by applicant]
Christoph Albermann, et al., “Synthesis of the milk oligosaccharide 2′-fucosyllactose using recombinant bacterial enzymes,” Carbohydrate Research, (2001), vol. 334, 97-103. [cited by applicant]
Florian Baumgartner, et al., “Synthesis of the Human Milk Oligosaccharide Lacto-NTetraose in Metabolically Engineered, Plasmid-Free [cited by applicant]
Nicolas Fierfort and Eric Samain, “Genetic engineering of [cited by applicant]
Caroline Gebus, et al., “Synthesis of a-galactosyl epitopes by metabolically engineered [cited by applicant]
Sang Yup Lee, et al., “Systems metabolic engineering, industrial biotechnology and microbial cell factories,” Microbial Cell Factories, (2012), vol. 11, No. 156, 1-3. [cited by applicant]
Clemens Kunz and Heinz Egge, “Chapter 1: From Bifidus Factor to Human Milk Oligosaccharides: A Historical Perspective on Complex Sugars in Milk,” Prebiotics and Probiotics in Human Milk Origins and Functions, (2016), 3-… [cited by applicant]
Tatsuo Miyazaki, et al., “Chapter 24: Enzymatic Synthesis of Lacto-N-Difucohexaose I Which Binds to [cited by applicant]
Takeomi Murata, et, al, “Facile enzymatic conversion of lactose into lacto-N-tetraose and lacto-N-neotetraose,” Glycoconjugate Journal, (1999), vol. 16, 189-195. [cited by applicant]
Rune T. Nordvang, et al., “Separation of 30-sialyllactose and lactose by nanofiltration: A trade-off between charge repulsion and pore swelling induced by high pH,” Separation and Purification Technology, (2014), vol. 1… [cited by applicant]
Altmann et al., 2016, Food Bioprocess Technol 9: 1924-1936. [cited by applicant]
Córdova et al., 2017, Chemical Engineering Research and Design, 117, 488-499. [cited by applicant]
Montesdeoca et al., 2016, Journal of Membrane Science, 520, 712-722. [cited by applicant]